Cannvas MedTech (CSE:MTEC) , a leading business technology company in the cannabis space, is pleased to announce the appointment of Khavita Harrycharran and Golfo Karageorgos to the newly formed Cannvas Women of Influence Advisory Panel, a collection of individuals who bring unique knowledge and skills which augment the knowledge and skills of the formal board of directors in order to more effectively guide the organization.

“I am very proud to announce the formation of the Cannvas Women of Influence Advisory Panel and welcome Khavita and Golfo as the first members,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “In this day and age we feel it is important to give women a voice in our organization to ensure its long term success. We can also benefit from an advisory panel with diverse backgrounds because those patients who can benefit from using medical cannabis to augment their own health and wellness come from all walks of life. I look forward to working closely with Khavita and Golfo as we build an active and effective advisory panel and prepare for the launch of our Cannvas.me online platform.”


The Cannvas Women of Influence will consist of key influencers and inspiring leaders from various industries and fields. The panel will enhance access and inclusion for women to fully participate in project discussions and operations for the organization based on their own experience. The group will meet on a monthly basis to review and scrutinize company projects and take on a responsible role within the Cannvas organization, and report back to the board of directors.

Roles and responsibilities of the advisory panel include:

  • encourage the development of a governance framework that enable sustainable growth,
  • develop an understanding of the medical cannabis business, market and industry trends and provide “wise counsel” on issues raised,
  • provide unbiased insights and ideas from third party points-of-view,
  • encourage and support the exploration of new business ideas and act as a resource for senior executives,
  • provide social networking platform for directors and the company
  • challenge directors and management to improve the business

As the Director of Program Management at Cannvas, Khavita oversees the complete life cycle of services and products delivered to our clients – ranging from the conceptual stage to delivery.  Her extensive background in project management paired with her technical expertise and creative flair enables her to deliver full-scale omni-channel solutions to our clients.

Khavita has successfully pursued numerous challenges in the interactive space to bring complex brands and businesses to the forefront of digital marketing and technology.  She successfully leads the Project Management practice at Cannvas MedTech by strategically scoping out new projects, managing internal and client contacts, monitoring project financials and coordinating the execution of a variety of projects at any given time.  Working as the delivery counterpart to the Marketing team, Khavita is the main conduit between the strategic arm of marketing and the delivery team that supports it. Her experience spans a wide variety of platforms, industries, clients and marketing agencies.  Previous client engagements have included work with FedEx, Kraft, Dell, Citibank, Citibank ThankYou Rewards, Nissan/Infiniti, Nestle Canada, Scotiabank, American Medical Association, Baxter, Baxalta, Shire, Merck and Sanofi.

After seven years of corporate experience working with esteemed Fortune 500 companies such as Ralph Lauren, where she focused on retail and financial planning, logistics and inventory control, Golfo Karageorgos branched off into the entrepreneurial world. For the past ten years, she has been successfully growing her New York based luxury brand in its brick-and-mortar and online presence.  With this enterprise, Golfo and her team have also designed, manufactured, and consulted for some of the largest luxury fashion houses and department stores throughout the world from the United States to Europe and Asia. Her business covers every part of the supply chain from initial sourcing to final product.  Committed to forging strong partnerships, while leveraging her expertise in the luxury sector, Golfo prides herself on focusing on trends and innovation within the retail industry, a commitment that keeps her company at the forefront of this fast-paced field.   Her ability to marry creative talent with operational excellence is crucial in today’s quickly changing business landscapes.

About Cannvas MedTech Inc.

Cannvas MedTech is a leading business technology company in the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

For additional information:

www.cannvasmedtech.com

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.

For further information: Media Inquiries media@cannvasmedtech.com; Investor Relations ir@cannvasmedtech.com, 1-800-489-0116

Click here to connect with Cannvas MedTech (CSE:MTEC) for an Investor Presentation. 

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less